Precision BioSciences Says USPTO to Re-examine Cellectis Patents

The USPTO is re-examining two patents licensed to Cellectis that are at the center of a suit filed last year by Cellectis against Precision BioSciences.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.